KR870001214A - 4,7-디히드로티에노[2,3-b]피리딘 유도체의 제조방법 - Google Patents

4,7-디히드로티에노[2,3-b]피리딘 유도체의 제조방법 Download PDF

Info

Publication number
KR870001214A
KR870001214A KR1019860005357A KR860005357A KR870001214A KR 870001214 A KR870001214 A KR 870001214A KR 1019860005357 A KR1019860005357 A KR 1019860005357A KR 860005357 A KR860005357 A KR 860005357A KR 870001214 A KR870001214 A KR 870001214A
Authority
KR
South Korea
Prior art keywords
methyl
pyridine
nitrophenyl
dihydro
carboxylate
Prior art date
Application number
KR1019860005357A
Other languages
English (en)
Other versions
KR930005175B1 (ko
Inventor
이꾸오 아다찌
요시하루 히라마쓰
모또히꼬 우에다
마사루 가와까미
Original Assignee
시오노기세이야꾸 가부시끼가이샤
요시또시 가즈오
시오노 기세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시오노기세이야꾸 가부시끼가이샤, 요시또시 가즈오, 시오노 기세이야꾸 가부시끼가이샤 filed Critical 시오노기세이야꾸 가부시끼가이샤
Publication of KR870001214A publication Critical patent/KR870001214A/ko
Application granted granted Critical
Publication of KR930005175B1 publication Critical patent/KR930005175B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음.

Description

4,7-디히드로티에노[2,3-b]피리딘 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 일반식(II)의 화합물을 하기 일반식(III) 화합물과 반응시킴을 특징으로 하는 하기 일반식(I)을 갖는 4,7-디히드로티에노[2,3-b]-피리딘 유도체의 제조방법.
    (식중, R1은 직쇄 또는 측쇄 C1-C4알킬, 알콕시알킬 또는 아릴알킬이고; R2는 수소, 직쇄 또는 측쇄 C1-C4알킬 또는 알콕시카르보닐이며; R3는 수소, 직쇄 또는 측쇄 C1-C4알킬, 1 또는 그 이상의 할로겐 또는 알콕시기로 치환가능한 페닐, 임의치환된 시클로알킬 또는 임의 치환된 시클로알킬이거나; 또는 R2및 R3는 함께 알킬렌을 형성할 수도 있다.)
  2. 제1항에 있어서, 메틸 4,7-디히드로-6-메틸-4-(3-니트로페닐)-3-페닐티에노[2,3-b]피리딘-5-카르복실레이트의 제조방법.
  3. 제1항에 있어서, 메틸 4,7-디히드로-6-메틸-4-(3-니트로페닐)-3-n-부틸티에노[2,3-b]피리딘-5-카르복실레이트의 제조방법.
  4. 제1항에 있어서, 메톡시에틸 4,7-디히드로-6-메틸-4-(3-니트로페닐)-3-n-부틸티에노[2,3-b]피리딘-5-카르복실레이트의 제조방법.
  5. 제1항에 있어서, 메틸 4,7-디히드로-6-메틸-4-(3-니트로페닐)-3-이소부틸티에노[2,3-b]피리딘-5-카르복실레이트의 제조방법.
  6. 제1항에 있어서, 메톡시에틸 4,7-디히드로-6-메틸-4-(3-니트로페닐)-3-이소부틸티에노[2,3-b]피리딘-5-카르복실레이트의 제조방법.
  7. 제1항에 있어서, 메틸 4,7-디히드로-6-메틸-4-(3-니트로페닐)-3-시클로펜틸메틸티에노[2,3-b]피리딘-5-카르복실레이트의 제조방법.
  8. 제1항에 있어서, 메틸 4,7-디히드로-6-메틸-4-(3-니트로페닐)-3-시클로헥실티에노[2,3-b]피리딘-5-카르복실레이트의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860005357A 1985-07-03 1986-07-02 4,7-디히드로티에노 [2,3-b] 피리딘 유도체의 제조방법 KR930005175B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP147054 1985-07-03
JP60147054A JPS6210087A (ja) 1985-07-03 1985-07-03 ４，７−ジヒドロチエノ〔２，３−ｂ〕ピリジン誘導体，その製造法および循環器系疾患治療剤

Publications (2)

Publication Number Publication Date
KR870001214A true KR870001214A (ko) 1987-03-12
KR930005175B1 KR930005175B1 (ko) 1993-06-16

Family

ID=15421457

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860005357A KR930005175B1 (ko) 1985-07-03 1986-07-02 4,7-디히드로티에노 [2,3-b] 피리딘 유도체의 제조방법

Country Status (7)

Country Link
US (1) US4703051A (ko)
EP (1) EP0207345B1 (ko)
JP (1) JPS6210087A (ko)
KR (1) KR930005175B1 (ko)
DE (1) DE3683549D1 (ko)
DK (1) DK174026B1 (ko)
GB (1) GB2177400B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777167A (en) * 1986-04-09 1988-10-11 Ortho Pharmaceutical Corporation Pharmaceutically useful substituted thiacycloalkeno [3,2-b]pyridines, compositions and method of use
US4874760A (en) * 1987-01-09 1989-10-17 Toa Eiyo, Ltd. 4,7-dihydroisothiazolo(5,4-b)pyridine derivatives and cardiovascular treating agents containing said derivatives
GB8801491D0 (en) * 1988-01-22 1988-02-24 Beecham Group Plc Novel compounds
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
JP3179132B2 (ja) * 1990-07-04 2001-06-25 塩野義製薬株式会社 非粘着性皮膜形成法
JP2632754B2 (ja) * 1991-05-21 1997-07-23 塩野義製薬株式会社 脳内グルタミン酸遊離抑制剤
US6037340A (en) * 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
JP3046589U (ja) * 1997-08-26 1998-03-10 株式会社三栄マシニング モンキ−スパナ−
ZA200605471B (en) * 2003-12-23 2007-11-28 Dow Agrosciences Llc Process for the preparation of pyridine derivatives
JP2007230869A (ja) * 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
EP1965796A2 (en) * 2005-12-20 2008-09-10 Gilead Colorado, Inc. 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2310746A1 (de) * 1973-03-03 1974-09-12 Bayer Ag Verfahren zur herstellung von neuen 1,4-dihydrochinolinen sowie ihre verwendung als arzneimittel
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
DD210278A5 (de) * 1982-03-05 1984-06-06 Boehringer Ingelheim Kg Verfahren zur herstellung neuer basisch substituierter 4-phenyl-4,5,6,7-tetrahydro-thieno-(2,3-c)pyridine
JPS5965089A (ja) * 1982-10-05 1984-04-13 Shionogi & Co Ltd ジヒドロピラゾロ〔３，４−ｂ〕ピリジン誘導体およびその製造法
JPS6056979A (ja) * 1983-09-08 1985-04-02 Shionogi & Co Ltd ４，７−ジヒドロピラゾロ〔３，４−ｂ〕ピリジン誘導体およびその製造法

Also Published As

Publication number Publication date
GB2177400A (en) 1987-01-21
JPS6210087A (ja) 1987-01-19
US4703051A (en) 1987-10-27
JPH0556358B2 (ko) 1993-08-19
DK315486A (da) 1987-01-04
KR930005175B1 (ko) 1993-06-16
DK174026B1 (da) 2002-04-29
DE3683549D1 (de) 1992-03-05
EP0207345A3 (en) 1988-02-24
EP0207345B1 (en) 1992-01-22
GB2177400B (en) 1989-04-05
DK315486D0 (da) 1986-07-02
EP0207345A2 (en) 1987-01-07
GB8616238D0 (en) 1986-08-13

Similar Documents

Publication Publication Date Title
KR870002125A (ko) 피리딘 유도체의 제조방법
KR880001651A (ko) 이미다조 [4,5-b] 피리딘 유도체, 그의 제조방법 및 그를 함유하는 항궤양제
KR880002823A (ko) 약제학적 화합물
KR870001214A (ko) 4,7-디히드로티에노[2,3-b]피리딘 유도체의 제조방법
KR870002056A (ko) 치환된 프로파르길옥시아세토니트릴 유도체의 제조 방법
ES8504719A1 (es) Un metodo para preparar derivados de 4-hidroxi-2-quinolona.
KR830007662A (ko) 5,6,7,7a-테트라하이드로-4H-티에노 [3,2-c]-피리딘-2-온 유도체의 제조방법
KR840008155A (ko) 트리아조로[4,3,-c] 피리미딘과 트리아조로[1,5-c]피리미딘의 제조방법
AU578395B2 (en) Antiallergic 5-alkyl-1-phenyl-2-piperazinoalkyl-pyrazoline- 3-one compounds
KR870003092A (ko) 피리딘 유도체의 제조방법
KR860001789A (ko) 디히드로피리딘 유도체의 제조방법
KR860008983A (ko) 4- 벤조일-1- 알킬(알켄일) 피라졸의 제조방법
KR850002979A (ko) 1,2,3-트리티안화합물의 신규 제조방법
KR830010090A (ko) 아닐린 유도체의 제조방법
KR870003074A (ko) 피라졸 유도체의 제조방법
KR870004038A (ko) 제초제 화합물의 제조방법
KR840007420A (ko) 치환된 카복시-티아졸로[3,2-α] 피리미딘 유도체의 제조방법
DE69007203T2 (de) Imidazolderivate, Verfahren zu deren Herstellung und diese enthaltende Antiulkusmittel.
DK61191A (da) Fremgangsmaade til fremstilling af 1alfa-silyloxy-4alfa-hydroxy-3beta-(3alfa-hydroxy-4-phenoxy-buten-1-yl)-cyclopent-2alfa-yl-alkynderivater
DE3679091D1 (de) Herstellung von thienoimidazolderivaten.
KR830009135A (ko) 4-피라졸릴 아린산 에스테르 유도체 및 그 제조방법
KR830004209A (ko) 옥타데센산 아미드의 제법
SE7901250L (sv) Nytt forfarande for framstellning av tiazolderivat
IE42053L (en) Phosphorus thiazole derivatives
KR860004063A (ko) 알킬리덴 디옥시 화합물의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010410

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee